Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $43.8 million.

  • Ocular Therapeutix's Accumulated Expenses rose 2482.56% to $43.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $43.8 million, marking a year-over-year increase of 2482.56%. This contributed to the annual value of $43.8 million for FY2025, which is 2482.56% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Accumulated Expenses of $43.8 million as of Q4 2025, which was up 2482.56% from $40.3 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Accumulated Expenses ranged from a high of $43.8 million in Q4 2025 and a low of $13.6 million during Q1 2021
  • Over the past 5 years, Ocular Therapeutix's median Accumulated Expenses value was $24.2 million (recorded in 2022), while the average stood at $25.6 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 18049.92% in 2021, then crashed by 2706.77% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Accumulated Expenses stood at $20.1 million in 2021, then grew by 19.76% to $24.1 million in 2022, then rose by 18.96% to $28.7 million in 2023, then rose by 22.5% to $35.1 million in 2024, then increased by 24.83% to $43.8 million in 2025.
  • Its Accumulated Expenses stands at $43.8 million for Q4 2025, versus $40.3 million for Q3 2025 and $34.4 million for Q2 2025.